Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND: Phase 3 BION-1301 in Adults with IgA Nephropathy
ChiCTR2500096892Phase 3Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing BION-1301 with Placebo (2 arms). Primary endpoints: Effect of BION-1301 versus placebo on proteinuria at Week 40 and Effect of BION-1301 versus placebo on proteinuria at Week 104. Started Feb 2025; status: recruiting.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2500096892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096892.